Project Grant R21AI199745
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Regents of the University of California, San Francisco (UCSF) a Project Grant of $666,065 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective June 1, 2026, through May 31, 2031. This five-year research initiative investigates the molecular mechanisms by which B cells distinguish self from foreign antigens to mount appropriate immunogenic responses. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $182,196 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the project period June 4, 2026 through May 31, 2028. The award funds research into antibody-driven bioconjugation strategies designed to chemically modify primary immune cells and disease-associated proteins. This...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $201,744 Project Grant on June 4, 2026, to The Regents of the University of California, San Francisco, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This five-year research initiative, scheduled for completion by May 31, 2031, will advance understanding of thymic T cell tolerance mechanisms relevant to autoimmune disease diagnosis and treatment. Dr....
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.05 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Virginia on September 12, 2025, with a completion date of August 31, 2029. This research initiative investigates paired receptor signaling in natural killer (NK) cells to understand antiviral immunity and viral control mechanisms. The project employs advanced molecular...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Regents of the University of California, San Francisco a Project Grant of $201,744 on April 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research through March 31, 2031. The research project will investigate transcriptional mechanisms that regulate dysregulated Type 17 mucosal inflammation via innate lymphoid cells (ILC3s), with the...
- Federal Project Grant Award Summary The University of California, San Diego received a $438,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 8, 2025, through June 30, 2027. The award supports basic immunological research focused on understanding the mechanisms that regulate immunoglobulin gene rearrangement, specifically investigating how enhancers and epigenetic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $659,663 to the Beckman Research Institute of the City of Hope under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 1, 2025, for a five-year project period concluding July 31, 2030. The grant supports fundamental research investigating the role of RNA modification in the development and function of invariant natural killer T (iNKT) cells, specialized...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $815,762 Project Grant to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 19, 2026, with a completion date of January 31, 2031. This research initiative will deliver quantitative scientific understanding of how biophysical properties of antibodies impact their capacity to evolve affinity...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $441,202 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, doing business as University of California, Berkeley, with an award date of June 12, 2025 and completion date of May 31, 2027. The grant funds basic immunological research investigating the role of ex-regulatory T cells (exTregs) in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded $246,000 to The Regents of the University of California, San Francisco on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research examining immunoreceptor tyrosine-based activation motifs (ITAMs) in natural killer (NK) cells. Through this project grant with a completion date of April 30, 2028, the awardee will conduct investigator-initiated biomedical research to elucidate the roles ITAMs play in NK cell activation and immune function. The research will utilize genetically modified mouse models to determine whether ITAMs influence NK cell development, phenotypic characteristics, and responsiveness to target cells, with the ultimate goal of enhancing cellular therapies and improving understanding of NK cell signaling cascades in immunosuppressive disease environments such as tumors. This award represents targeted investment in basic immunological science intended to advance therapeutic applications in cellular immunotherapy. The research outcomes will generate scientific knowledge about NK cell activation mechanisms and may inform optimization of immune cell-based therapeutic approaches for infectious diseases, cancer, and other conditions where NK cell function is critical to disease control.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $246.0k | 5/20/26 |